市售人类胚胎培养基的组成分析
该研究分析了7家供应商的47种人类胚胎培养基及蛋白补充剂(共80份样本)中40种成分的浓度。结果显示各品牌间存在共同趋势,但成分差异明显,无两种培养基组成相同;即使同一母公司旗下品牌也有差异。作者认为全面披露培养基成分对循证改进至关重要。
要点
- 大多数受精培养基葡萄糖浓度为2.5-3 mM,所有卵裂期培养基为0.5 mM或以下,大多数囊胚期培养基为2.5-3.3 mM。
- 连续型培养基的葡萄糖浓度通常接近卵裂期培养基。
- 乳酸、甘氨酸和钾等其他成分在不同品牌间存在明显差异,无两种培养基组成相同。
核心结论
- 各品牌培养基存在共同趋势,但成分差异明显,表明人类胚胎培养基配方缺乏明确标准。
- 全面披露和完全透明地公开人类胚胎培养基成分(包括每种成分的精确浓度)对循证改进培养基至关重要。
研究设计与样本
- 于2019年12月至2020年6月期间购买了47种不同的人类胚胎培养基和蛋白补充剂,包括完全培养基(n=23)、未补充培养基(n=14)和补充剂(n=10)。
- 未补充培养基用同品牌每种可用补充剂进行补充(n=33种组合)。
- 所有样本直接冷冻于液氮并储存于-80°C直至成分分析,共收集80份样本,测定了40种成分的浓度。
主要发现
- 使用Cobas 8000分析仪测定了7种电解质(钙、氯、铁、镁、磷酸盐、钾、钠)、葡萄糖、免疫球蛋白A、G、M(IgA、IgG、IgM)、尿酸、丙氨酸氨基转移酶(ALAT)、天冬氨酸氨基转移酶(ASAT)、白蛋白以及总蛋白浓度。
- 使用超高效液相色谱-串联质谱(UPLC-MS/MS)分析了丙酮酸、乳酸、肉碱和21种氨基酸。
- 所有品牌的序贯培养基系统中葡萄糖浓度呈现高-低-高模式:大多数受精培养基为2.5-3 mM,所有卵裂期培养基为0.5 mM或以下,大多数囊胚期培养基为2.5-3.3 mM。
- 连续型培养基的葡萄糖浓度通常接近卵裂期培养基。
- 乳酸、甘氨酸和钾等其他成分在不同品牌间存在明显差异,无两种胚胎培养基组成相同,即使同一母公司旗下品牌也有差异。
关键数值与推荐
- 大多数受精培养基葡萄糖浓度为2.5-3 mM。
- 所有卵裂期培养基葡萄糖浓度为0.5 mM或以下。
- 大多数囊胚期培养基葡萄糖浓度为2.5-3.3 mM。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 研究采用靶向方法并进行了部分检测,限制了成分分析仅针对该组分析物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: What is the composition of currently available commercial human embryo culture media provided by seven suppliers, for each stage of human preimplantation embryo development? SUMMARY ANSWER: While common trends existed across brands, distinct differences in composition underlined the absence of a clear standard for human embryo culture medium formulation. WHAT IS KNOWN ALREADY: The reluctance of manufacturers to fully disclose the composition of their human embryo culture media generates uncertainty regarding the culture conditions that are used for human preimplantation embryo culture. The critical role of the embryo culture environment is well-recognized, with proven effects on IVF success rates and child outcomes, such as birth weight. The lack of comprehensive composition details restricts research efforts crucial for enhancing our understanding of its impacts on these outcomes. The ongoing demand for greater transparency remains unmet, highlighting a significant barrier in embryo culture medium optimization. STUDY DESIGN, SIZE, DURATION: For this study, 47 different human embryo culture media and protein supplements were purchased between December 2019 and June 2020; they comprise complete media (n = 23), unsupplemented media (n = 14), and supplements (n = 10). Unsupplemented media were supplemented with each available supplement from the same brand (n = 33 combinations). All samples were directly frozen in liquid nitrogen and stored at -80°C until composition analysis. PARTICIPANTS/MATERIALS, SETTING, METHODS: We determined the concentrations of 40 components in all samples collected (n = 80). Seven electrolytes (calcium, chloride, iron, magnesium, phosphate, potassium, sodium), glucose, immunoglobulins A, G, and M (IgA, IgG, IgM), uric acid, alanine aminotransferase (ALAT), aspartate aminotransferase (ASAT), and albumin, as well as the total protein concentration, were determined in each sample using a Cobas 8000 Analyser (Roche Diagnostics). Analysis of pyruvate, lactate, carnitine, and 21 amino acids was achieved with Ultra-High Performance Liquid Chromatography-Mass Spectrometry (UPLC-MS/MS). MAIN RESULTS AND THE ROLE OF CHANCE: Our analysis showed that generally, the concentrations of components of ready-to-use human embryo culture media align with established assumptions about the changing needs of an embryo during early development. For instance, glucose concentrations displayed a high-low-high pattern in sequential media systems from all brands: 2.5-3 mM in most fertilization media, 0.5 mM or below in all cleavage stage media, and 2.5-3.3 mM in most blastocyst stage media. Continuous media generally resembled glucose concentrations of cleavage stage media. However, for other components, such as lactate, glycine, and potassium, we observed clear differences in medium composition across different brands. No two embryo culture media compositions were the same. Remarkably, even embryo culture media from brands that belong to the same parent company differed in composition. Additionally, the scientific backing for the specific concentrations used and the differences in the composition of sequential media is quite limited and often based on minimal in vivo studies of limited sample size or studies using animal models. LARGE SCALE DATA: N/A. LIMITATIONS, REASONS FOR CAUTION: We used a targeted approach and performed a selection of tests which limit the composition analysis to this set of analytes. WIDER IMPLICATIONS OF THE FINDINGS: Comprehensive disclosure and complete transparency concerning the composition of human embryo culture media, including the exact concentration of each component, are crucial for evidence-based improvements of culture media for human preimplantation embryos. STUDY FUNDING/COMPETING INTEREST(S): This research was supported by ZonMw (https://www.zonmw.nl/en), Programme Translational Research 2 (project number 446002003). M.G. declares an unrestricted research grant from Ferring not related to the presented work, paid to the institution VU Medical Center. The remaining authors have no conflicts of interest to declare. TRIAL REGISTRATION NUMBER: N/A.
引用
- Zagers MS, Laverde M, Goddijn M, et al. The composition of commercially available human embryo culture media. Hum Reprod. 2025. PMID: 39585967. doi:10.1093/humrep/deae248
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。